SK279813B6 - Farmaceutický prostriedok, spôsob jeho prípravy a - Google Patents

Farmaceutický prostriedok, spôsob jeho prípravy a Download PDF

Info

Publication number
SK279813B6
SK279813B6 SK3756-91A SK375691A SK279813B6 SK 279813 B6 SK279813 B6 SK 279813B6 SK 375691 A SK375691 A SK 375691A SK 279813 B6 SK279813 B6 SK 279813B6
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
weight
methoxybenzoyl
cyclopentyloxycarbonyl
amino
Prior art date
Application number
SK3756-91A
Other languages
English (en)
Slovak (sk)
Inventor
James J. Holohan
Ieuan J. Edwards
Robert J. Timko
Randy J. Bradway
Arlene Clements
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK279813(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909027014A external-priority patent/GB9027014D0/en
Priority claimed from GB919115107A external-priority patent/GB9115107D0/en
Application filed by Zeneca Limited filed Critical Zeneca Limited
Publication of SK279813B6 publication Critical patent/SK279813B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK3756-91A 1990-12-12 1991-12-11 Farmaceutický prostriedok, spôsob jeho prípravy a SK279813B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027014A GB9027014D0 (en) 1990-12-12 1990-12-12 Pharmaceutical agents
GB919115107A GB9115107D0 (en) 1991-07-12 1991-07-12 Pharmaceutical agents

Publications (1)

Publication Number Publication Date
SK279813B6 true SK279813B6 (sk) 1999-04-13

Family

ID=26298105

Family Applications (2)

Application Number Title Priority Date Filing Date
SK3756-91A SK279813B6 (sk) 1990-12-12 1991-12-11 Farmaceutický prostriedok, spôsob jeho prípravy a
SK664-98A SK279814B6 (sk) 1990-12-12 1998-05-20 Spôsob prípravy n-[4-[5-(cyklopentyloxykarbonyl)am

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK664-98A SK279814B6 (sk) 1990-12-12 1998-05-20 Spôsob prípravy n-[4-[5-(cyklopentyloxykarbonyl)am

Country Status (30)

Country Link
US (6) US5319097A (de)
EP (1) EP0490648B1 (de)
JP (1) JP2585495B2 (de)
KR (2) KR0183027B1 (de)
CN (2) CN1043405C (de)
AP (1) AP285A (de)
AT (1) ATE131048T1 (de)
AU (1) AU656157B2 (de)
BE (1) BE1004229A5 (de)
CA (2) CA2056066C (de)
CZ (1) CZ283181B6 (de)
DE (2) DE4140858A1 (de)
DK (1) DK0490648T3 (de)
ES (1) ES2079589T3 (de)
FI (1) FI101193B (de)
FR (1) FR2670488B1 (de)
GB (2) GB2280606B (de)
GR (1) GR3018318T3 (de)
HK (2) HK81597A (de)
HU (2) HU213211B (de)
IE (1) IE75348B1 (de)
IL (1) IL100091A (de)
IT (1) IT1256282B (de)
MX (1) MX9102473A (de)
MY (1) MY106315A (de)
NZ (1) NZ240939A (de)
PH (1) PH30928A (de)
RU (1) RU2106140C1 (de)
SK (2) SK279813B6 (de)
TW (1) TW276181B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
DE9410461U1 (de) * 1994-07-01 1994-09-22 Merck Patent Gmbh, 64293 Darmstadt Mittel für die Röntgenfluoreszenzanalyse
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
IN182496B (de) * 1996-02-20 1999-04-17 Reddy Research Foundation
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
KR100283682B1 (ko) * 1998-07-14 2001-03-02 조정래 열풍건조장치
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
IN191496B (de) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
EP1216058A2 (de) * 1999-09-20 2002-06-26 Alza Corporation Verfahren zur verminderung der polymorphen umwandlung eines arzneistoffs
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
TWI337083B (en) * 2001-01-26 2011-02-11 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1406880A1 (de) * 2001-07-10 2004-04-14 PHARMACIA & UPJOHN COMPANY Crystalline thiazin-oxazolidinone
EP3168218B1 (de) * 2001-08-15 2018-11-14 Pharmacia & Upjohn Company LLC Ein kristall enthaltend ein malatsalz von n-[2-(diethylamino)ethyl]-5-[(5-fluor-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamid zur verwendung als medikament
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE345793T1 (de) * 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE406364T1 (de) * 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
ES2318274T3 (es) * 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
EP1855651A4 (de) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen heterocyclischer amidderivate
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
CA2695008A1 (en) * 2007-07-30 2009-02-05 Auspex Pharmaceuticals, Inc. Substituted indoles
US20090149662A1 (en) * 2007-12-05 2009-06-11 Raghupathi Reddy Anumula Processes for preparing zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CA2936332A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
WO2018140858A1 (en) 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
WO2019130334A1 (en) 2017-12-28 2019-07-04 Council Of Scientific & Industrial Research Process for the preparation of zafirlukast and analogs thereof
WO2022243942A1 (en) 2021-05-19 2022-11-24 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds

Also Published As

Publication number Publication date
FR2670488B1 (fr) 1994-01-28
US6143775A (en) 2000-11-07
CN1043405C (zh) 1999-05-19
DK0490648T3 (da) 1996-05-06
US5482963A (en) 1996-01-09
BE1004229A5 (fr) 1992-10-13
FI101193B1 (fi) 1998-05-15
ITMI913324A0 (it) 1991-12-11
US5504216A (en) 1996-04-02
GB9126354D0 (en) 1992-02-12
FI101193B (fi) 1998-05-15
CA2319308C (en) 2001-08-21
IL100091A (en) 1998-08-16
KR970005014A (ko) 1997-01-29
GB9418154D0 (en) 1994-10-26
GB2251791B (en) 1995-05-17
US5993859A (en) 1999-11-30
DE69115229D1 (de) 1996-01-18
RU2106140C1 (ru) 1998-03-10
CA2056066C (en) 2002-04-02
HU213211B (en) 1997-03-28
ATE131048T1 (de) 1995-12-15
TW276181B (de) 1996-05-21
MX9102473A (es) 1992-06-01
US5319097A (en) 1994-06-07
SK279814B6 (sk) 1999-04-13
AP285A (en) 1993-09-23
US5612367A (en) 1997-03-18
CA2319308A1 (en) 1992-06-13
AU656157B2 (en) 1995-01-27
JP2585495B2 (ja) 1997-02-26
KR0183027B1 (ko) 1999-05-01
CA2056066A1 (en) 1992-06-13
CZ283181B6 (cs) 1998-01-14
GR3018318T3 (en) 1996-03-31
AP9100340A0 (en) 1992-01-31
CN1243827A (zh) 2000-02-09
CN1062291A (zh) 1992-07-01
HK81397A (en) 1997-06-27
GB2280606A (en) 1995-02-08
HUT61281A (en) 1992-12-28
FI915826A (fi) 1992-03-31
ES2079589T3 (es) 1996-01-16
GB2251791A (en) 1992-07-22
CN1105705C (zh) 2003-04-16
EP0490648B1 (de) 1995-12-06
KR100207802B1 (ko) 1999-07-15
DE69115229T2 (de) 1996-05-09
FR2670488A1 (fr) 1992-06-19
HU913865D0 (en) 1992-02-28
GB2280606B (en) 1995-05-17
HK81597A (en) 1997-06-27
IE75348B1 (en) 1997-08-27
IE914310A1 (en) 1992-06-17
ITMI913324A1 (it) 1993-06-11
FI915826A0 (fi) 1991-12-11
PH30928A (en) 1997-12-23
EP0490648A1 (de) 1992-06-17
IL100091A0 (en) 1992-08-18
IT1256282B (it) 1995-11-29
MY106315A (en) 1995-04-29
AU8899491A (en) 1992-06-18
JPH04266824A (ja) 1992-09-22
KR920011493A (ko) 1992-07-24
DE4140858A1 (de) 1992-06-17
NZ240939A (en) 1994-05-26
HU211126A9 (en) 1995-10-30
CS375691A3 (en) 1992-06-17

Similar Documents

Publication Publication Date Title
SK279813B6 (sk) Farmaceutický prostriedok, spôsob jeho prípravy a
EP0490649B1 (de) Eine physikalische Form von N-[4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzolsulfonamid, ein Verfahren zu dessen Herstellung und es enthaltende pharmazeutische Zusammensetzungen
KR102572035B1 (ko) 무정형 형태의 빌란테롤 트리페나테이트 및 이의 제조방법
AU3095600A (en) New pharmaceutical formulation
EP3572069A1 (de) Erhöhung der löslichkeit und bioverfügbarkeit von enzalutamid
FI106021B (fi) Menetelmä N-[4-[5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yyli-metyyli]-3-metoksibentsoyyli]-2-metyylibentseenisulfonamidin fysikaalisen muodon valmistamiseksi
NO179575B (no) Farmasöytisk preparat inneholdende en fysikalsk form av forbindelsen N-[4-[5-(cyklopentyloksykarbonyl)amino-1-metylindol-3-ylmetyl-3-metoksybenzoylÅ-2-metylbenzensulfonamid
PT100508B (pt) Composicoes farmaceuticas e processo para a sua preparacao
HU220769B1 (hu) N-[ 4-(5-/Ciklopentil-oxi-karbonil-amino/-l-metil-indol-3-il-metil)-3-metoxi-benzoil]-2-metil-benzolszulfonamid új fizikai módosulata és eljárás annak előállítására
CZ20001102A3 (cs) Tabletová formulace pro trvalé uvolňování látky k léčbě Parkinsouovy nemoci

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20111211